|Day Low/High||252.09 / 258.91|
|52 Wk Low/High||173.12 / 264.97|
Don't just follow the herd, time your exits and entrances well -- even if it is a big player like Warren Buffett that is leading the charge.
Market leadership may be lacking on Thursday despite rising trading volumes, plus an update on Apple, Microsoft, Mastercard, Amazon and Gilead.
Here's how to play the biotech with earnings on the horizon.
So far, earnings season has not been the obstacle that many have feared.
They buy and buy and buy. The same stocks. Over and over. No end to it.
RMPIA ended January up 0.8%, but now the damage from the Wuhan virus is weighing on the future.
It's no secret that the Fed would like to get out of the short-term repo business.
What I suggest individual investors do is give their portfolios a physical. Like a visit to the doctor.
This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.
Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.
AMGN appears to have taken a turn for the better and is now looking at targets of $254 and $270.
Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.
Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.
According to the charts, the drugmaker should break out to new highs.
These stocks are priced for total imperfection. That's just what you want.
Markets are watching what Fed Chair Powell will signal for future rate cuts during this afternoon's FOMC rate decision.
If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
Before I give my recommendation I want to visit with the charts and indicators.
RMPIA is up 20.9% in the first nine months of 2019.
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.
Let's check out the charts to get a sense of where prices could be headed.
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.